Zacks: Analysts Expect VBI Vaccines Inc. (NASDAQ:VBIV) Will Announce Earnings of -$0.08 Per Share

Equities research analysts expect that VBI Vaccines Inc. (NASDAQ:VBIVGet Rating) will announce earnings per share (EPS) of ($0.08) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for VBI Vaccines’ earnings. VBI Vaccines posted earnings of ($0.07) per share during the same quarter last year, which suggests a negative year over year growth rate of 14.3%. The firm is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that VBI Vaccines will report full year earnings of ($0.31) per share for the current financial year, with EPS estimates ranging from ($0.34) to ($0.29). For the next financial year, analysts expect that the business will report earnings of ($0.24) per share, with EPS estimates ranging from ($0.29) to ($0.16). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for VBI Vaccines.

VBI Vaccines (NASDAQ:VBIVGet Rating) last issued its earnings results on Monday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.07). The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.14 million. VBI Vaccines had a negative net margin of 11,054.36% and a negative return on equity of 42.79%.

A number of research firms have recently weighed in on VBIV. Jefferies Financial Group assumed coverage on VBI Vaccines in a research report on Thursday, December 30th. They set a “buy” rating and a $6.00 target price for the company. Raymond James cut their target price on VBI Vaccines from $9.00 to $6.00 and set a “strong-buy” rating on the stock in a report on Tuesday, March 8th. Finally, Zacks Investment Research raised VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Tuesday, April 5th.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Balyasny Asset Management LLC acquired a new position in VBI Vaccines in the third quarter valued at $2,718,000. Goldman Sachs Group Inc. raised its position in shares of VBI Vaccines by 243.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,153,567 shares of the biopharmaceutical company’s stock worth $2,699,000 after acquiring an additional 818,173 shares in the last quarter. Millennium Management LLC lifted its stake in shares of VBI Vaccines by 44.5% in the 4th quarter. Millennium Management LLC now owns 1,741,498 shares of the biopharmaceutical company’s stock valued at $4,075,000 after purchasing an additional 535,968 shares during the period. BlackRock Inc. boosted its position in shares of VBI Vaccines by 3.6% during the 4th quarter. BlackRock Inc. now owns 13,269,221 shares of the biopharmaceutical company’s stock valued at $31,049,000 after purchasing an additional 462,785 shares in the last quarter. Finally, UBS Group AG grew its stake in VBI Vaccines by 703.1% during the third quarter. UBS Group AG now owns 460,199 shares of the biopharmaceutical company’s stock worth $1,431,000 after purchasing an additional 402,895 shares during the period. 43.61% of the stock is owned by institutional investors and hedge funds.

NASDAQ:VBIV traded down $0.05 during trading hours on Monday, reaching $1.65. 1,699,773 shares of the company were exchanged, compared to its average volume of 2,326,024. The business has a 50 day moving average of $1.54 and a 200 day moving average of $2.23. VBI Vaccines has a 1-year low of $1.21 and a 1-year high of $4.31. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.00 and a quick ratio of 3.92. The company has a market capitalization of $424.55 million, a P/E ratio of -6.11 and a beta of 1.97.

VBI Vaccines Company Profile (Get Rating)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

Featured Stories

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.